Should pharmaceutical prices be regulated? The strengths and weaknesses of the British pharmaceutical price regulation scheme

Davis, Peter

dc.contributor.author	Davis, Peter	en
dc.date.accessioned	2013-10-03T03:42:53Z	en
dc.date.issued	1998	en
dc.identifier.citation	Health Care Analysis 6(2):168-169 1998	en
dc.identifier.issn	1065-3058	en
dc.identifier.uri	http://hdl.handle.net/2292/20869	en
dc.relation.ispartofseries	Health Care Analysis	en
dc.rights	Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0 http://www.sherpa.ac.uk/romeo/issn/1065-3058/	en
dc.rights.uri	https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm	en
dc.title	Should pharmaceutical prices be regulated? The strengths and weaknesses of the British pharmaceutical price regulation scheme	en
dc.type	Journal Article	en
dc.identifier.doi	10.1007/BF02678123	en
pubs.issue	2	en
pubs.begin-page	168	en
pubs.volume	6	en
pubs.end-page	169	en
dc.rights.accessrights	http://purl.org/eprint/accessRights/RestrictedAccess	en
pubs.subtype	Review	en
pubs.elements-id	563	en
pubs.record-created-at-source-date	2010-09-01	en